News
Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY ...
Are weight loss shots like Ozempic and Wegovy safe long-term? It’s complicated. Some early studies suggest thyroid concerns ...
Skye Bioscience nears Phase IIa data for nimacimab, targeting obesity treatment gaps with robust preclinical insights.
The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...
Reiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025Patient enrollment in ...
SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.
Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.
The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...
A post hoc analysis of the SUMMIT trial, published in JACC, reveals that baseline body mass index (BMI) and fat distribution ...
The drugmaker is a large and consistent client for Covington. The law firm has represented Novo Nordisk in several dozen ...
Some studies have linked the popular weight-loss drugs with a potentially higher risk of eye problems and vision loss. Should ...
Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results